drugset
drugset / Trial / NCT00024011

PS-341 in Treating Patients With Metastatic Malignant Melanoma

NCT00024011 ↗

Phase 2 Completed 50 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

Phase II trial to study the effectiveness of PS-341 in treating patients who have metastatic malignant melanoma. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die

Timeline

Start
2001-07
Primary completion
2006-09
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Bortezomib Small molecule — Intravenous

Indications

metastatic melanoma